BioAegis Therapeutics Garners $3,000,000 New Financing Round

  • Feed Type
  • Date
  • Company Name
    BioAegis Therapeutics
  • Mailing Address
    Undisclosed Boston, MA 02108
  • Company Description
    BioAegis Therapeutics’ products will restore depleted levels of plasma gelsolin, an integral and ubiquitous, natural human protein, whose important clinical role is now emerging. Extensive animal and human studies support the theory that the body’s natural reservoir of plasma gelsolin keeps inflammation local, while its deficiency leads to inflammatory dysregulation and may cause catastrophic consequences like multiple organ failure, shock and death.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    The money will be used for continued development of its products focused on the repletion of human plasma gelsolin.
  • M&A Terms
  • Venture Investor

Trending on Xconomy